Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
MCSeres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB)

NASDAQ Global Select · Currency in USD
$2.09 ▼ -0.04 (-1.88%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.21 ▲ +0.12 (+5.74%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$2.13
Open
$2.13
Day's Range
$2.01 – $2.16
52 Week Range
$2.00 – $29.98
Volume
69,712
Avg. Volume
80,389
Market Cap
$20.78M
Beta (5Y Monthly)
0.22
PE Ratio (TTM)
--
EPS (TTM)
-$2.33
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$12.00

Profile: Seres Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
66
CEO
Richard N. Kender

Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$1.01 · Revenue est. $6.35M
DateEst.Actual
Aug 5, 2026-$2.18$0.47Beat
May 5, 2026-$1.88-$2.08Miss
Mar 12, 2026-$2.39-$1.78Beat
Nov 5, 2025$0.05$0.94Beat
Aug 6, 2025-$2.72-$2.27Beat
May 7, 2025-$0.67-$3.75Miss

Analyst view

Consensus price target
$12.00 ▲ +474.2%
Range $12.00 – $12.00
Rating: Buy
Buy 61% · Hold 17% · Sell 22%

Get free alerts on MCRB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.